Kuros Biosciences (KURN) H1 2024 earnings summary

Executive summary

• Achieved 148% year-over-year revenue growth in H1 2024, reaching CHF 31.8 million, driven by MagnetOs platform expansion and commercial execution.

• Transitioned to a pure MedTech company, de-risking the business and focusing on high-growth opportunities, with a robust product pipeline.

• Maintained a strong financial position with no debt and CHF 14.3 million in cash as of June 30, 2024.

• Expanded U.S. and international market presence, with MagnetOs commercialized in 16 countries and cleared in 22.

• Strong clinical data for MagnetOs, including Level I evidence of superior efficacy over autograft in spinal fusion.

Financial highlights

• Total revenue rose from CHF 12.9 million to CHF 31.8 million, a 148% increase over H1 2023.

• Adjusted EBITDA reached CHF 4 million, or 12.5% margin, ahead of plan.

• MagnetOs segment EBITDA margin was 27%, with segment EBITDA of CHF 8.6 million.

• Gross margin improved to around 90% due to higher production volume and reduced overhead per unit.

• Cash and cash equivalents stood at CHF 14.3 million as of June 30, 2024.

Outlook and guidance

• H2 expected to contribute 57-60% of annual sales, implying up to CHF 80 million for FY 2024.

• Adjusted EBITDA margin guidance for FY 2024 is 10-12%, with break-even operating cash flow targeted in H2.

• Midterm EBITDA margin expected to grow slightly over the next 2-3 years.

• Targeting 10% of revenue from international markets in the midterm.

• Continued investment in infrastructure, personnel, and production capacity.